Xin Jing Bao·2025-09-17 10:28Core Viewpoint - The announcement regarding the insider trading investigation of Jiang Wei, a major shareholder and actual controller of Haohai Biological Technology Co., Ltd., has raised concerns among investors about the company's future, despite the company's claims that the incident is unrelated to its operations [1][2]. Group 1: Company Background - Haohai Biological Technology was founded in 2007 and has evolved into a technology-driven enterprise engaged in the research, production, and sales of medical devices and pharmaceuticals, focusing on aesthetic medicine and wound care, ophthalmology, and orthopedic products [5]. - The company was listed on the Hong Kong Stock Exchange in April 2015 and later on the Shanghai Stock Exchange's Sci-Tech Innovation Board in October 2019 [5]. Group 2: Shareholder Structure - Jiang Wei and You Jie are the controlling shareholders, holding 28.53% and 17.29% of the shares, respectively, making them the first and second largest shareholders [3]. - Jiang Wei is also the ultimate beneficiary of a partnership that holds 1% of the company's shares, indicating a significant influence over the company's governance [3]. Group 3: Financial Performance - In 2024, Haohai Biological reported revenue of 2.698 billion yuan, a mere 1.64% increase compared to previous years, indicating a significant slowdown in growth [5]. - The company experienced a decline in revenue and net profit in the first half of 2025, with revenue dropping by 7.12% to 1.304 billion yuan and net profit decreasing by 10.29% to 211 million yuan [6]. - The three main business segments—medical aesthetics, ophthalmology, and orthopedics—saw revenue declines of 9.31%, 18.61%, and 2.58%, respectively, in the first half of 2025 [6]. Group 4: Management and Strategy - The company's operational management is handled by a professional team led by key figures such as Hou Yongtai and Wu Jianying, who hold significant positions within the company [3]. - The company has reported a 21.53% decrease in R&D expenses, with the R&D expense ratio falling to 7.54% from 8.93% in the previous year, attributed to the completion of core projects [6].